FY’19 Total Revenue of $626.4 Million, +4.7% vs. FY’18 
FY’19 Net Income of $87.2 Million, +58.5% vs. FY’18FY’19 GAAP EPS of $0.98 per Diluted Share vs. $0.64 per Diluted Share in FY’18FY’19 Adjusted EPS of $1.32 per Diluted Share vs. $1.28 per Diluted Share in FY’18FY’19 Adjusted EBITDA of $179.6 Million, +10.6% vs. FY’18FY’19 Operating Cash Flow a Record $133.2 Million, +38.1% vs. FY’18IRVING, Texas, Feb. 21, 2020 (GLOBE NEWSWIRE) — HMS Holdings Corp. (Nasdaq: HMSY) today announced financial results for the fourth quarter and full year ended December 31, 2019. “HMS posted solid revenue and profit growth in full year 2019, with revenue increasing 4.7%, net income rising 58.5% and adjusted EBITDA increasing 10.6% from the prior year, along with record operating cash flow performance,” said Bill Lucia, Chairman and CEO. “While our business can experience quarterly variability, on an annual basis we continue to experience top and bottom line growth driven by our product innovation, application of new technologies and expansion within both current and new clients.“We expect our growth in 2020 will be fueled by investments in sales talent, technology, data analytics and product development as well as the strategic acquisitions completed last year as we deliver increasing value to our expanding client base this year and in the future,” Lucia concluded.Fourth QuarterTotal revenue in the fourth quarter of 2019 was $163.4 million, compared to total revenue of $155.8 million in the fourth quarter of 2018 (+4.9%).Coordination of Benefits (COB) revenue was $98.6 million in the fourth quarter of 2019 compared to $98.9 million in the fourth quarter of 2018 (-0.3%). Payment Integrity (PI) revenue was $48.4 million in the fourth quarter of 2019, compared to $40.9 million in the fourth quarter of 2018 (+18.3%). Population Health Management (PHM) revenue was $16.6 million in the fourth quarter of 2019, compared to $16.0 million in the prior year fourth quarter (+3.8%).Net income in the fourth quarter of 2019 was $17.3 million, or $0.20 per diluted share, compared to net income of $33.4 million, or $0.38 per diluted share, in the fourth quarter of 2018. Adjusted EBITDA in the fourth quarter of 2019 was $42.3 million, compared to $46.1 million in the fourth quarter of 2018 (-8.2%). Adjusted EPS in the fourth quarter of 2019 was $0.27 per diluted share, compared to adjusted EPS of $0.48 per diluted share in the fourth quarter of 2018, which included discrete tax benefits of $0.17 per diluted share. Excluding the discrete tax benefits, adjusted EPS in the fourth quarter of 2018 was $0.31 per diluted share.Full YearTotal revenue for the twelve months ended December 31, 2019 was $626.4 million, compared to $598.3 million in the prior year (+4.7%). For the twelve months ended December 31, 2019, total revenue included $10.5 million from the 2Q 2019 Reserve Release. During the second quarter of 2019, the Company released its remaining contract related balances under its original Medicare RAC Contract (the “2Q 2019 Reserve Release”). For the twelve months ended December 31, 2018, total revenue included $8.4 million from the Medicare RAC reserve release in the first quarter of 2018 (the “1Q 2018 Reserve Release”). Excluding the 2Q 2019 Reserve Release and the 1Q 2018 Reserve Release (the “Reserve Releases”), total revenue increased 4.4% compared to the prior year.COB revenue for the twelve months ended December 31, 2019 was $404.1 million, compared to $397.1 million in the prior year (+1.8%). PI revenue for the twelve months ended December 31, 2019 was $162.2 million, compared to $144.0 million in the prior year (+12.6%). Excluding the Reserve Releases, PI revenue increased 11.9% compared to the prior year. PHM revenue for the twelve months ended December 31, 2019 was $60.1 million, compared to $57.1 million in the prior year (+5.2%).Net income for the twelve months ended December 31, 2019 was $87.2 million, or $0.98 per diluted share, compared to $55.0 million, or $0.64 per diluted share, in the prior year. For the twelve months ended December 31, 2019, net income included $0.07 per diluted share related to the 2Q 2019 Reserve Release, a net benefit of $0.06 per diluted share related to a gain on the sale of an investment (the “3Q 2019 Gain on Investment”), and discrete tax benefits recorded in the first quarter totaling $0.07 per diluted share. For the twelve months ended December 31, 2018, net income included a net benefit of $0.05 per diluted share related to the 1Q 2018 Reserve Release, discrete tax benefits recorded during the year totaling $0.19 per diluted share and an expense of $20.0 million relating to the settlement of litigation in connection with an acquisition the Company completed in 2010 (the “Settlement Expense”).Adjusted EBITDA for the twelve months ended December 31, 2019 was $179.6 million including a net benefit of $8.2 million related to the 2Q 2019 Reserve Release and $7.7 million related to the 3Q 2019 Gain on Investment, compared to $162.3 million in the prior year (+10.6%), including a net benefit of $6.3 million related to the 1Q 2018 Reserve Release. Excluding those benefits, Adjusted EBITDA increased 4.9% compared to the prior year.Adjusted EPS for the twelve months ended December 31, 2019 was $1.32 per diluted share, including $0.07 per diluted share related to the 2Q 2019 Reserve Release, $0.06 per diluted share related to the 3Q 2019 Gain on Investment, and discrete tax benefits recorded in the first quarter totaling $0.07 per diluted share. Adjusted EPS was $1.28 per diluted share in the prior year, including a net benefit of $0.05 per diluted share related to the 1Q 2018 Reserve Release and discrete tax benefits recorded during the year totaling $0.19 per diluted share. Excluding the 2Q 2019 Reserve Release, the 3Q 2019 Gain on Investment, discrete tax items in 2019 and 2018, and the 1Q 2018 Reserve Release, adjusted EPS for the twelve months ended December 31, 2019 was $1.12 per diluted share, compared to $1.04 per diluted share in the prior year (+7.7%).Cash Flow and Capital ResourcesNet cash provided by operating activities for the twelve months ended December 31, 2019 was a record $133.2 million compared to $96.5 million in the prior year (+38.1%). Capital expenditures were $21.6 million for the twelve months ended December 31, 2019, compared to $30.4 million in the prior year (-28.9%).During the third quarter of 2019, the Company acquired VitreosHealth, a privately-held company that offers predictive and prescriptive health insights for population risk models. HMS acquired VitreosHealth for approximately $36.6 million, which was funded with cash on hand. During the fourth quarter of 2019, the Company acquired Accent, a payment accuracy and cost containment business. HMS acquired Accent for approximately $158.6 million, which was funded with cash on hand.The Company’s balance sheet at December 31, 2019 included $139.3 million of cash and cash equivalents and $240.0 million in outstanding bank debt, compared to cash and cash equivalents of $178.9 million and outstanding bank debt of $240.0 million at December 31, 2018.Financial GuidanceThe Company initiated its full year 2020 financial guidance, as follows:(1) Reported FY 2019 revenue includes $10.5 million related to the 2Q 2019 Reserve Release. Including the 2Q 2019 Reserve Release, total FY 2020 revenue growth is expected to be 12.6 – 14.2%. Excluding the 2Q 2019 Reserve Release, then total FY 2020 revenue growth is expected to be 14.5 – 16.2%.(2) Reported FY 2019 net income includes $6.0 million related to the 2Q 2019 Reserve Release, $5.6 million related to the 3Q 2019 Gain on Investment and $6.5 million related to discrete tax benefits. Including the 2Q 2019 Reserve Release, 3Q 2019 Gain on Investment and discrete tax benefits, then FY 2020 net income growth is expected to be (12.6) – (8.0)%. Excluding the 2Q 2019 Reserve Release and 3Q 2019 Gain on Investment, net income growth is expected to be 10.1 – 15.9%.(3) Reported 2019 adjusted EBITDA includes $8.2 million related to the 2Q 2019 Reserve Release and $7.7 million related to the 3Q 2019 Gain on Investment. Including the 2Q 2019 Reserve Release and 3Q 2019 Gain on Investment, adjusted EBITDA growth is expected to be 2.8 – 6.7%. Excluding the 2Q 2019 Reserve Release and 3Q 2019 Gain on Investment, then FY 2020 adjusted EBITDA growth is expected to be 12.8 – 17.1%.Key assumptions underlying the Company’s full year 2020 financial guidance include:Depreciation and amortization of approximately $51 millionStock-based compensation expense of approximately $23 millionNet interest expense of approximately $6 millionAn effective tax rate of 28-30%Capital expenditures of approximately $30-35 millionWebcast and Conference Call InformationHMS will report its preliminary fourth quarter and full year 2019 financial and operating results via webcast at 7:30 AM CT / 8:30 AM ET on Friday, February 21, 2020. The webcast will include discussion of HMS developments, forward-looking statements and other material information about business and financial matters. The webcast can be accessed via phone at 877-303–7208 (224-357–2389 for international participants), or on the HMS Investor Relations website at http://investor.hms.com/events-and-presentations. The webcast will be archived and available for replay at http://investor.hms.com/events-and-presentations. This press release and the financial statements contained herein are also available on the HMS Investor Relations website at http://investor.hms.com/press-releases.About HMSHMS advances the healthcare system by helping healthcare organizations reduce costs and improve health outcomes. Through our industry-leading technology, analytics and engagement solutions, we save billions of dollars annually while helping consumers lead healthier lives. HMS provides a broad range of coordination of benefits, payment integrity and population health management solutions that help move the healthcare system forward. Visit us at www.hms.com and follow us on Twitter at @HMSHealthcare.TrademarksHMS and the HMS logo are registered trademarks of HMS Holdings Corp. and/or its affiliates. Other names may be trademarks of their respective owners.Non-GAAP Financial MeasuresThe Company reports and discusses its operating results using financial measures consistent with accounting principles generally accepted in the United States (“GAAP”). From time to time, in press releases, financial presentations, earnings conference calls or otherwise, the Company may disclose certain non-GAAP financial measures. The non-GAAP financial measures presented in this press release should not be viewed as alternatives or substitutes for the Company’s reported GAAP results. A reconciliation to the most directly comparable GAAP financial measure is set forth in the tables that accompany this release.The Company believes that the non-GAAP financial measures presented in this press release are relevant and provide useful information to the Company’s management, investors, and other interested parties about the Company’s operating performance because the measures allow them to understand and compare the Company’s actual and expected operating results during the prior, current and future periods in a more consistent manner. The non-GAAP measures presented in this press release may not be comparable to similarly titled measures used by other companies. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provides a more complete understanding of the results of operations and trends affecting the Company’s business. These non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to financial measures calculated in accordance with GAAP.Safe Harbor StatementThe financial results in this press release reflect preliminary, unaudited results, which are not final until the Company’s Form 10-K is filed. This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as “aims,” “anticipates,” “believes,” “estimates,” “expects,” “forecasts,” “future,” “intends,” “likely,” “may,” “outlook,” “plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,” “trends,” “will,” “would,” “could,” “should,” variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to future actions, including potential future share repurchases, business plans, objectives and prospects, future operating or financial performance and projections, including our full year guidance for 2020. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements. Factors that could cause or contribute to such differences, include, but are not limited to: our ability to execute our business plans and growth strategy; our ability to innovate, develop or implement new or enhanced solutions or services; the nature of investment, acquisition, strategic relationship and divestiture opportunities we are pursuing, and our ability to execute on such opportunities; our ability to successfully integrate acquired businesses and realize synergies; significant and increased competition for our solutions and services; variations in our results of operations; our ability to accurately forecast the revenue under our contracts and solutions; our ability to protect our systems from damage, interruption or breach, and to maintain effective information and technology systems and networks; our ability to protect our intellectual property rights, proprietary technology, information processes, and know-how; our failure to maintain a high level of customer retention or the unexpected reduction in scope or termination of key contracts with major customers; customer dissatisfaction or our non-compliance with contractual provisions or regulatory requirements; our failure to meet performance standards triggering significant costs or liabilities under our contracts; our inability to manage our relationships with data sources and suppliers; our reliance on subcontractors and other third party providers and parties to perform services; our ability to secure future contracts and favorable contract terms through the competitive bidding process; pending or threatened litigation; unfavorable outcomes in legal proceedings; our success in attracting and retaining qualified employees and members of our management team; our ability to generate sufficient cash to cover our interest and principal payments under our credit facility; changes in tax laws, regulations or guidance or unexpected changes in our effective tax rate; unanticipated increases in the number or amount of claims for which we are self-insured; accounting changes or revisions; risks relating to our international operations, including political, regulatory, economic, foreign exchange, cybersecurity, tax compliance and other risks; changes in the healthcare environment or healthcare financing system, including regulatory, budgetary or political actions that affect healthcare spending or the practices and operations of healthcare organizations; our failure to comply with applicable laws and regulations governing individual privacy and information security, domestically or internationally, or to protect such information from theft and misuse; our ability to comply with current and future legal and regulatory requirements; negative results of government or customer reviews, audits or investigations; state or federal limitations related to outsourcing of certain government programs or functions; restrictions on bidding or performing certain work due to perceived conflicts of interests; the market price of our common stock and lack of dividend payments; anti-takeover provisions in our corporate governance documents; and other factors, risks and uncertainties described in our most recent Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission. Any forward-looking statements are made as of the date of this press release. Except as may be required by law, we disclaim any obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
HMS HOLDINGS CORP. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share amounts)
(unaudited)HMS HOLDINGS CORP. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(unaudited)
HMS HOLDINGS CORP. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands, unaudited)
HMS HOLDINGS CORP. AND SUBSIDIARIES
(unaudited)Reconciliation of Net Income to EBITDA and Adjusted EBITDA

HMS HOLDINGS CORP. AND SUBSIDIARIES
(unaudited)Reconciliation of Net Income to GAAP EPS (Diluted) and Adjusted EPS (Diluted)
(1) Tax effect of adjustments is computed as the pre-tax effect of the adjustments multiplied by the adjusted annual effective tax rate at period end.(2) Diluted GAAP EPS and Diluted Adjusted EPS included discrete tax benefits of $0.17 per diluted share for the fourth quarter of 2018. Diluted GAAP EPS and Diluted Adjusted EPS included (i) discrete tax benefits of $0.07 per diluted share primarily related to the exercise of employee stock options, $0.07 per diluted share related to the Reserve Releases benefit and a $0.06 per diluted share benefit related to the 3Q 2019 Gain on Investment benefit for the twelve months ended December 31, 2019, and (ii) discrete tax benefits of $.0.19 per diluted share and $0.05 per diluted share related to the Reserve Releases benefit for the twelve months ended December 31, 2018. The discrete tax benefits recorded in the three months and twelve months ended December 31, 2018 primarily related to state tax apportionments, the closure of routine outstanding prior year tax audits, the exercise of employee stock options, the abandonment of subsidiary stock related to a 2010 acquisition, and year-end federal and state tax adjustments or provision true ups.(3) The Reserve Releases benefit of $0.07 per diluted share for the twelve months ended December 31, 2019 is net of income tax of approximately $0.03 per diluted share and the 3Q 2019 Gain on Investment benefit of $0.06 per diluted share for the twelve months ended December 31, 2019 is net of income tax of approximately $0.02 per diluted share. The Reserve Releases benefit of $0.05 per diluted share for the twelve months ended December 31, 2018 is net of income tax of approximately $0.02 per diluted share.
HMS HOLDINGS CORP. AND SUBSIDIARIES
(unaudited)Reconciliation of Total Debt to Net Leverage Ratio(4) Total Debt consists of the outstanding principal under our senior secured revolving credit facility
(5) Trailing twelve months Net income
(6) Trailing twelve months Adjusted EBITDA
(7) The Company’s net leverage ratio is calculated by dividing total net debt by trailing twelve months’ Adjusted EBITDA
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
The Company believes that the non-GAAP free cash flow financial measures presented in this press release provide useful information regarding how much cash flow is available, after purchases of property and equipment and investment in capitalized software, to be used for working capital needs or for other opportunities. It should not be inferred that the entire non-GAAP free cash flow amount is available for discretionary expenditures. These non-GAAP measures may not be comparable to similarly titled measures used by other companies.
Reconciliation of Projected 2020 Net Income to Projected 2020 EBITDA and Adjusted EBITDA

Bay Street News